Linda Yaccarino Resigns as CEO of Elon Musk's X after Two Years on the Job
Don't Miss TipRanks' Half-Year Sale
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
In a farewell post on X, Yaccarino reflected on her time at the company by saying that it had been 'the opportunity of a lifetime' to help carry out Musk's vision. She thanked him for trusting her with the mission of supporting free speech and turning X into an 'Everything App.' While she didn't give a reason for her exit, a source told NBC News that her departure had been planned for over a week. Musk responded to her announcement with a brief message, 'Thank you for your contributions.'
Before joining X, Yaccarino led NBCUniversal's global advertising division and was brought in to manage business operations at X, especially during a time of significant changes to the platform's content policies. She often defended Musk publicly, even after he made offensive remarks to advertisers at the 2023 DealBook Summit. Despite the backlash, Yaccarino stood by the company's position on free speech and urged advertisers to support what she described as a unique balance between open expression and business partnerships.
What Is the Prediction for Tesla Stock?
When it comes to Elon Musk's companies, most of them are privately held. However, retail investors can invest in his most popular company, Tesla (TSLA). Turning to Wall Street, analysts have a Hold consensus rating on TSLA stock based on 13 Buys, 13 Holds, and nine Sells assigned in the past three months, as indicated by the graphic below. Furthermore, the average TSLA price target of $294.42 per share implies that shares are trading near fair value.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
How the Trump–Musk relationship complicates Tesla's future
Tesla (TSLA) CEO Elon Musk's close ties with President Trump initially gave many investors hope for faster progress on initiatives like robotaxis and autonomous driving. Barron associate editor Al Root explains why that optimism was overblown and discusses the risks the Musk–Trump relationship still poses. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. Al, you know, it's interesting because I had some bulls on this program, Al. And part of their bullishness, full stop, was the relationship between Trump and Musk. Their thinking being, listen, it is a great thing for Musk to have this good friend in the White House who can perhaps foam the runway on some of these initiatives like robo taxis. Yeah, I mean, so the primary you just reiterated it or I'll just reiterate it. The primary benefit from the trust Trump Musk relationship was supposed to be nationwide uh autonomous driving standards, uh which would speed the adoption of this trillion dollar valuation that Dan Ives has for Dan Ives, for instance, and others have for robo taxis. Um, that was a bit Listen, I mean, you know, should I said it then? Maybe we did, maybe we didn't. It was a bit euphoric, right? The idea that just a relationship between the President and Elon Musk could create, you know, a trillion dollars in value, which it basically did overnight, right? Tesla stock, I can't remember, but we're talking like 480 in December. Um, so that was a bit euphoric. Uh so we probably overcooked that, just like we overcooked it on the downside when we thought the world was ending. I think the Trump Musk relationship is just sort of a risk for Tesla investors, and it kind of goes back to Musk's time, right? Is he going to stay involved in politics? Is he going to form a new political party? That's sort of like the downside risk. Uh, but if things sort of blow over and we just have to deal with like losing tax credits, then I think that, you know, we'll we'll sort of we can move on from the bromance and just sort of focus on whether they can sell cars and whether they can expand the robo taxis.
Business Insider
13 minutes ago
- Business Insider
Tesla tells staff it plans to roll out its Robotaxi service in San Francisco this weekend
Tesla told staff on Thursday it plans to launch its Robotaxi service in San Francisco this weekend, according to an internal memo viewed by Business Insider. The company said its timeline for the launch had been moved up and the service could launch as soon as Friday. Some Tesla owners will be sent an invite to use the service, the memo said, and users will pay for Robotaxi rides. The geofenced area where Robotaxi service will operate covers a large swath of the Bay Area, including Marin, much of the East Bay, San Francisco, and stretching south to San Jose, according to the memo. The program will launch with safety drivers in the driver's seat who will be able to control the car using the steering wheel and brakes, it said. A spokesperson for the California DMV said the agency recently met with Tesla, but the company has yet to apply for a permit for driverless testing or deployment. The agency did not respond to questions regarding whether Tesla would be required to have a permit to launch its service with a safety monitor in the driver's seat. The California Public Utilities Commission granted Tesla a permit to provide a transportation service for employees, but as of July 10, Tesla had not applied for any permits that would allow it to provide a commercial service to the public, BI previously reported. The CPUC did not immediately respond to a request for comment outside its normal working hours on Friday. Elon Musk said during Tesla's quarterly earnings call on Wednesday that its Robotaxis will operate with a safety operator in the front seat during the initial deployment in the Bay area. In Austin, where Tesla launched its Robotaxi service last month, the carmaker currently has safety monitors that sit in the passenger seat of the vehicle and remote operators that can intervene if the vehicle goes off course. Tesla did not respond to a request for comment sent outside normal working hours. Tesla started its Robotaxi launch in Austin with just over 10 vehicles in a geofenced area that the company has since expanded. The service is currently invite-only. In preparation for the Robotaxi launch, Tesla built modified Model Ys at its factory in Austin, BI previously reported. The vehicles were fitted with slightly different parts than a traditional Model Y, including additional camera equipment and a second telecommunications unit. Earlier this month, Musk said on X that the company would launch the service in the Bay Area within one to two months. Musk said during Wednesday's earnings call that Tesla was in the process of getting regulatory approval in California. Musk has said the company plans to expand its service globally, but for now, it is also seeking approval in Florida and Arizona. Business Insider previously reported that Tesla had scaled up its autonomous testing capabilities in California, more than tripling the number of workers testing in the state. In December, the electric-car maker registered 224 in-house test drivers and 104 vehicles in the state for an autonomous testing permit, according to public records viewed by Business Insider. Earlier this month, Tesla shared a video showing its first fully autonomous delivery: a Tesla Model Y driving itself from the Austin factory to a customer's house. Tesla's AI Director, Ashok Elluswamy, said on X that the car reached speeds of 72 miles per hour at one point.
Yahoo
20 minutes ago
- Yahoo
Piper Sandler Says These 2 Stocks Are Top Picks for the Second Half of 2025
There's no magic formula for picking winning stocks, but having the right guide can make all the difference. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. That's where Wall Street's analysts come in. With a front-row seat to market movements and company performance, these pros make it their business to spot standout opportunities. And now, with 2025 beyond the halfway mark, it's the perfect moment to check in on the names they're backing for the rest of the year. Watching the current mid-year situation for Piper Sandler, analyst Jason Bednar lays out the attributes he's looking for in top-pick stocks, writing: 'Key themes across our top names include confidence we have in management's execution against guidance and Street estimates for the coming quarters, balance sheet flexibility that is good and/or improving, and risk/reward that skews favorably based on a combination of catalysts and valuation on shares.' With this in mind, we dug into the TipRanks database to get the broader Wall Street take on two of his top picks, and both are rated Buy, with the potential for double-digit gains. Let's break down the names, the numbers, and what makes them stand out. STERIS (STE) First up on our list, STERIS, is a medical technology (medtech) company. STERIS was founded in 1985 and is based in Ohio; the company got its start specializing in low-temperature liquid sterilization of surgical instruments. Today, the company is a global leader in infection prevention, offering a line of products and services designed to support patient care for a better medical outcome. To achieve that goal, STERIS offers a diverse array of products, including medical consumables such as detergents, endoscopy accessories, and barrier devices. On the service side, the company can install and maintain medical equipment, provide sterilization for medical devices, repair medical instruments and scopes, and provide lab testing. Finally, STERIS can also provide its customers with larger-scale capital equipment, such as surgical tables, automated endoscope reprocessors, and even integrated connectivity solutions for today's high-tech operating rooms. STERIS offers its products under several categories, and reports its revenue under the categories Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The largest of these is Healthcare, which accounted for approximately 73% of the company's total revenue in its last reported quarter. That quarter was fiscal 4Q25 (March quarter), for which STERIS reported $1.5 billion in total revenue. This was up 4% year-over-year and beat the forecast by $30 million. At the bottom line, STERIS realized a quarterly adjusted net income of $2.74 per diluted share, a figure that was 14 cents above expectations. The company's free cash flow rose year-over-year, from $620.3 million to $787.2 million in the current report. Checking in with Piper Sandler, we find that analyst Bednar wastes no time in explaining why this stock made his list. Bednar writes, 'Why is it a top idea? STE is a model of consistency, posting MSD+ top-line and HSD/LDD bottom-line growth in six of the past seven years, underpinned by healthy end markets, disciplined capital allocation and a focus on lean operations. For medtech investors, that's a model deserving of a premium valuation. Growth in the high-margin AST segment has improved sequentially for six consecutive quarters, and the segment growth outlook has gotten cleaner of late… Balance sheet leverage is as light as it's been in several years (~1.3x net leverage), and this Board/mgmt team have a bias to accretive M&A.' Based on this stance, Bednar rates STE shares as Overweight (i.e., Buy), with a $280 price target to suggest a one-year upside potential of 24%. (To watch Bednar's track record, click here) The consensus rating here is a Moderate Buy, based on 5 Buy and 2 Hold ratings. Meanwhile, the $270.33 average target price indicates room for an upside of 20% by this time next year. (See STE stock forecast) Merit Medical Systems (MMSI) The second stock we're looking at here is another medtech, Merit Medical Systems. This firm, based in the suburbs of Salt Lake City, Utah, is known as a developer, manufacturer, and distributor of medical devices, particularly devices used in interventional, diagnostic, and therapeutic procedures. Merit Medical's product lines feature proprietary designs, and are intended to be disposable; they are most often used in the fields of cardiology, radiology, oncology, critical care, and endoscopy. Merit Medical has a global footprint, with some 7,300 employees, including an international team of marketers and clinical support that totals more than 800. The company is recognized as a global leader in disposable medical tools. The company boasts a market cap of $5 billion. Earlier this month, Merit suffered a sharp blow to its stock price, falling as much as 10% on July 16, after a regulatory disclosure. That disclosure involved a warning letter from the FDA, regarding issues of quality control at one of the company's manufacturing facilities. These types of warnings are not uncommon from regulators, but in this case, the timing is a problem – Merit is currently expanding its product lines, and a warning letter of this type may have a stronger impact than usual. The company has already stated that it is working in concert with the FDA to address the issues raised in the letter. Looking at Merit's product lines, we find that the company has its hands in a wide range of categories. To give a small list: the company produces hemostasis accessories, dialysis equipment, safety kits, infusion systems, pulmonary stents, GI dilation balloons, and blood sampling devices. The company also provides educational resources, including on-demand courses and recorded webinars, to provide tutorials on its various equipment lines and products. We can also note that on May 6 this year, Merit announced its latest regulatory approval, with Health Canada's approval of Merit's Wrapsody Cell-Impermeable Endoprosthesis. The company is also undergoing a leadership change, and current CEO Fred Lampropoulos will be stepping down in October. His place will be taken by Martha Aronson, effective on October 3. Mr. Lampropoulos will remain as Chairman of the Board. Merit's last quarterly report covered 1Q25, and in that quarter the company had revenues of $355.4 million. This was up 10% year-over-year and beat the forecast by $2.8 million. The non-GAAP EPS figure, of 86 cents, beat expectations by 11 cents per share. Checking in again with Piper Sandler's Bednar, we see the analyst weighing various pros and cons here, writing, 'MMSI has demonstrated durable and consistent growth and management has been superb in managing investor expectations over the past 4+ years… Management already positively pre-announced 2Q and detailed CEO transitions plans, but we also see an EPS beat and guidance raise as being in order. The WRAPSODY reimbursement strategy will be a focal point after failing to secure TPT on management's previously announced timeline, but we're optimistic the developments to date will result in this being more of a short delay for securing TPT.' Summing up, Bednar sees this medtech as a solid choice, and advises investors to buy in, saying of MMSI, 'Longer-term, we believe an extension of what's been a solid execution story should keep MMSI one of the premium mid-cap assets in medtech.' These comments are complemented by an Overweight (i.e., Buy) rating, and a price target which, at $110, points toward a one-year gain of 29%. This stock has earned a Strong Buy from the Street's analysts, a consensus based on 10 recent reviews that split 9 to 1 in favor of Buy over Hold. The shares are currently trading for $85.06 and the average price target of $108.80 implies the stock will gain 28% in the next 12 months. (See MMSI stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. Disclaimer & DisclosureReport an Issue Sign in to access your portfolio
